LONDON -- Tesco
After trading as high as 385 pence in May, shares in�Tesco� (LSE: TSCO ) (NASDAQOTH: TSCDY ) were today down at 328 pence. That's a 15% fall in just one month. However, Tesco's low price-to-earnings ratio and significant dividend yield will now be attracting value and income investors.
Tesco is forecast to pay a dividend of 15.2 pence for the full year. At today's price, that's a 4.6% yield. If the supermarket manages to hit expectations for the year of 32.9 pence, the forecast P/E is just 10. According to my statistics, only nine other shares in the FTSE 100 are cheaper on both metrics.
Tesco is not excruciatingly cheap. That said, it's more than three years since the shares spent any meaningful time under 300 pence.
Croda International
Croda International� (LSE: CRDA ) is one of the FTSE 100's great success stories. Five years ago, the company had just reported 33.5 pence of earnings per share and the shares traded hands for 631 pence. Fast-forward to today, and 137 pence of EPS is expected for the full year. The shares are now priced at 2,260 pence.
Top 5 Long Term Companies For 2015: Boston Scientific Corp (BSX)
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women�� Health, Neuromodulation, and Electrophysiology. In January 2011, it completed the acquisition of Intelect Medical, Inc. In January 2011, it completed the acquisition of Sadra Medical, Inc. In March 2011, the Company completed the acquisition of Atritech, Inc. In February 2011, it announced the acquisitions of S.I. Therapies and ReVascular Therapeutics, Inc. In January 2011, the Company sold its Neurovascular business to Stryker Corporation. In June 2012, the Company acquired Cameron Health, Inc. of San Clemente, California and, as a result, added to its product portfolio subcutaneous implantable cardioverter defibrillator, called the S-ICD System.
Interventional Cardiology
The Company offers coronary stent product. Coronary stents are tiny, mesh tubes used in the treatment of coronary artery disease, which are implanted in patients to prop open arteries and facilitate blood flow to and from the heart. The Company offers a two-drug platform strategy with its paclitaxel-eluting and everolimus-eluting stent system offerings, and it offers a range of stent sizes. The Company markets its next-generation internally-developed and self-manufactured PROMUS Element stent system in the United States, its Europe/Middle East/Africa (EMEA) region and certain Inter-Continental countries, including China and India. It markets the PROMUS everolimus-eluting stent system, supplied to the Company by Abbott Laboratories, in Japan. It also markets its TAXUS paclitaxel-eluting stent line, including its third-generation TAXUS Element paclitaxel-eluting stent system in the U.nited States, Japan, EMEA and certain Inter-Continental countries.
The Compa! ny markets a line of products used to treat patients with atherosclerosis, a principal cause of coronary artery obstructive disease. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA). The Company markets a family of intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels. The iLab Ultrasound Imaging System continues as its flagship console and is compatible with its line of imaging catheters. The system is designed to enhance the diagnosis and treatment of blocked vessels and heart disorders. Sadra is developing a repositionable and retrievable device for transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis. The Lotus Valve System consists of a stent-mounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve. Atritech has developed a device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. The WATCHMAN Left Atrial Appendage Closure Technology, developed by Atritech, is the first device proven in a randomized clinical trial to offer an alternative to anticoagulant drugs, and is approved for use in CE Mark countries.
Cardiac Rhythm Management
The Company develops, manufactures and markets a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including Implantable cardioverter defibrillator (ICD) systems used to detect and treat abnormally fast heart rhythms (tachycardia) that could result in sudden cardiac death, including implantable cardiac resynchronization therapy defibrillator (CRT-D) systems used to treat heart failure, and implantable pacemaker systems used to manage slow or irregular heart rhyth! ms (brady! cardia), including implantable cardiac resynchronization therapy pacemaker (CRT-P) systems used to treat heart failure. Its product offerings include its COGNIS cardiac resynchronization therapy defibrillator (CRT-D), its TELIGEN ICD systems and its ALTRUA family of pacemaker systems. During 2011, it began the United States launch of its next-generation line of defibrillators, INCEPTA, ENERGEN and PUNCTUA.
Endoscopy
The Company markets a range of products to diagnose, treat and ease a variety of digestive diseases, including those affecting the esophagus, stomach, liver, pancreas, duodenum, and colon. Common disease states include esophagitis, portal hypertension, peptic ulcers as well as esophageal, biliary, pancreatic and colonic cancer. The Company offers the Radial Jaw 4 Single-Use Biopsy Forceps, which are designed to enable collection of large high-quality tissue specimens without the need to use large channel therapeutic endoscopes. Its exclusive line of RX Biliary System devices are designed to provide greater access and control for physicians to diagnose and treat challenging conditions of the bile ducts, such as removing gallstones, opening obstructed bile ducts and obtaining biopsies in suspected tumors. The Company also markets the Spyglass Direct Visualization System for direct imaging of the pancreatico-biliary system. The Spyglass System is a single-operator cholangioscopy device that offers clinicians a direct visualization of the pancreatico-biliary system and includes supporting devices for tissue acquisition, stone management and lithotripsy. Its products also include the WallFlex family of stents, in particular, the WallFlex Biliary line and WallFlex Esophageal line; and in 2011, the Company launched its Advanix Biliary Plastic Stent System and the Expect Endoscopic Ultrasound Aspiration Needle in the United States and certain international markets. Its Resolution Clip Device is an endoscopic mechanical clip designed to treat gastrointestinal bleeding.
T! he Company markets devices to diagnose, treat and ease pulmonary disease systems within the airway and lungs. Its products are designed to help perform biopsies, retrieve foreign bodies from the airway, open narrowings of an airway, stop internal bleeding, and ease symptoms of some types of airway cancers. Its product line includes pulmonary biopsy forceps, transbronchial aspiration needles, cytology brushes and tracheobronchial stents used to dilate narrowed airway passages or for tumor management. Asthmatx, Inc. designs, manufactures and markets a less-invasive, catheter-based bronchial thermoplasty procedure for the treatment of severe persistent asthma. The Alair Bronchial Thermoplasty System, developed by Asthmatx, has both CE Mark and Food and Drug Administration (FDA) approval and is the first device-based asthma treatment approved by the FDA.
Peripheral Interventions
The Company sells various products designed to treat patients with peripheral disease, including a line of medical devices used in percutaneous transluminal angioplasty and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. In 2010 and 2011, it launched several of its products internationally, including the EPIC self-expanding nitinol stent system in certain international markets, and the Carotid WALLSTENT stent system in Japan. The Company launched three new peripheral angioplasty balloons in 2011, including its next-generation Mustang percutaneous transluminal angioplasty (PTA) balloon, its Coyote balloon catheter, a highly deliverable and ultra-low profile balloon dilatation catheter designed for a range of peripheral angioplasty procedures and its Charger PTA Balloon Catheter, a 0.035 inch percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation, as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company has commenced a limited ma! rket rele! ase of its OFFROAD re-entry catheter system in certain international markets, and in February 2012, it launched its TRUEPATH intraluminal CTO device in the United States.
The Company sells products designed to treat patients with non-vascular disease. Its non-vascular suite of products include biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continues to market its extensive line of Interventional Oncology product solutions, including the Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company�� FilterWire EZ Embolic Protection System is a filter designed to capture embolic material that may become dislodged during a procedure, which could otherwise travel into the microvasculature where it could cause a heart attack or stroke. It is commercially available in the United States, its EMEA region and certain Inter-Continental countries for multiple indications, including the treatment of disease in peripheral, coronary and carotid vessels. It is also available in the United States for the treatment of saphenous vein grafts and carotid artery stenting procedures.
Urology/Women�� Health
The Company�� Urology/Women�� Health division develops, manufactures and sells devices to treat various urological and gynecological disorders. The Company sells a variety of products designed to treat patients with urinary stone disease, stress urinary incontinence, pelvic organ prolapse and excessive uterine bleeding. The Company offers a line of stone management products, including ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons and catheters.
The Company markets a range of devices for the treatment of conditions, such as female urinary incontinence, pelvic floor reconstruction (rebuilding of the anatomy to its original state), and ! menorrhag! ia (excessive menstrual bleeding). It offers a breadth of mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits, and suturing devices. The Company markets its Genesys Hydro ThermAblator (HTA) system, a next-generation endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. The Genesys HTA System features a smaller and lighter console, simplified set-up requirements, and an enhanced graphic user interface and is designed to improve operating performance.
Neuromodulation
The Company within its Neuromodulation business markets the Precision Spinal Cord Stimulation (SCS) system, used for the management of chronic pain. In 2011, the Company launched its Clik Anchor for its Precision Plus SCS System, a rechargeable SCS device for chronic pain management. During 2011, it received FDA approval for and launched the Infinion 16 Percutaneous Lead, a 16-contact percutaneous lead. The Company also markets the Linear 3-4 and Linear 3-6 Percutaneous Leads for use with its SCS systems, which are designed to provide physicians more treatment options for their chronic pain patients. Intelect Medical, Inc. is a development-stage company developing advanced visualization and programming for the Vercise system.
Electrophysiology
The Company within its Electrophysiology business develops less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart. Included in its product offerings are radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Its products include the Blazer and Blazer Prime line of temperature ablation catheters, designed to deliver enhanced performance, responsiveness, and durability. Its cooled ablation portfolio includes the closed-loop irrigated catheter on the market, the Chilli II cooled! ablation! catheter, and the newly launched Blazer Open-Irrigated ablation catheter with a Total Tip Cooling Design.
The Company competes with Abbott Laboratories, Medtronic, Inc., St. Jude Medical, Inc. and Johnson & Johnson.
Advisors' Opinion:- [By Dan Carroll and Max Macaluso, Ph.D.]
In that time, a few key trends have stood out that investors should take note of ��particularly before Boston Scientific's (NYSE: BSX ) earnings emerge this Thursday. Fool contributor Dan Carroll and health care analyst Max Macaluso discuss how the above companies fared this earnings season, and if the trends we've seen will come to shape Boston Scientific's earnings as well later this week.
- [By Dan Caplinger]
Right out of the gate, Abbott found some success, getting FDA approval for its XIENCE Xpedition drug-eluting stent. The stent market could prove increasingly important for Abbott going forward, as its Absorb line of products moves through clinical trials. Boston Scientific (NYSE: BSX ) has a competing product, its Synergy line, which looks like the only potential roadblock for Abbott to capture first-mover status in bioresorbable stents.
- [By Brian Orelli]
Dragging down sales were medical devices, which saw sales drop 3% at constant currency. Much of the decline came from sales of its drug-eluting stent and related products, which fell 15% in the U.S. compared to the first quarter of 2012. U.S. sales are being dragged down by pricing pressure as it competes with Boston Scientific (NYSE: BSX ) and decreased usage by the doctors. Boston Scientific reported a similar experience with U.S. sales of drug-eluting stents down a whopping 33%.
- [By Sue Chang and Saumya Vaishampayan]
$BSX: Boston Scientific Corp. (BSX) �shares gained 3.2%. The medical devices marker�� Vercise Deep Brain Stimulation system won European approval to treat dystonia, a neurological disorder that causes involuntary muscle contractions.
Top 10 Low Price Stocks To Invest In Right Now: WebMD Health Corp (WBMD)
WebMD Health Corp. provides health information services to consumers, physicians and other healthcare professionals, employers, and health plans through its public and private online portals, mobile platforms, and health-focused publications in the United States. The company?s public portals enable consumers to obtain health and wellness information, including information on specific diseases or conditions; check symptoms; locate physicians; store individual healthcare information; receive periodic e-newsletters on topics of individual interest; and participate in online communities with peers and experts. Its public portals for physicians and healthcare professionals provide access to clinical reference sources; stay abreast of the latest clinical information; learn about new treatment options; earn continuing medical education credit; and communicate with peers. The company also provides mobile health information applications for use by consumers and physicians. In addit ion, WebMD Health Corp. offers e-detailing promotion and physician recruitment services, content syndication and distribution, and information services, as well as print services, including the advertisements in WebMD the Magazine, a consumer magazine distributed to physician office waiting rooms. The public portals? sponsors and advertisers include pharmaceutical, biotechnology, medical device, and consumer products companies. The company?s private portals enable employers and health plans to provide their employees and members with access to personalized health and benefit information and decision support technology that helps them to make more informed benefit, treatment, and provider decisions. Further, it offers telephonic health coaching services on a per participant basis across an employee or plan population for clients of its private portals. The company was founded in 1995 and is headquartered in New York, New York.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
In trading on Monday, technology shares were relative leaders, up on the day by about 1.18 percent. Among the leading sector stocks, gains came from WebMD Health (NASDAQ: WBMD) and 21Vianet Group (NASDAQ: VNET). Telecommunications services shares gained by just 0.35 percent in the US market today.
Top 10 Low Price Stocks To Invest In Right Now: OncoSec Medical Inc (ONCS)
OncoSec Medical Incorporated, incorporated on February 8, 2008, is an emerging drug-medical device company. The Company focused on designing, developing and commercializing medical approaches for the treatment of solid cancers. In March 2011, the Company acquired from Inovio Pharmaceuticals, Inc. (Inovio) certain assets related to the use of drug-medical device combination products for the treatment of different cancers.
The Company�� acquired assets relate to certain non-deoxyribonucleic acid (DNA) vaccine technology and property relating to selective tumor ablation technologies, which it refers to as the OncoSec Medical System (OMS), a therapy which uses an electroporation device to facilitate delivery of chemotherapy agents, or nucleic acids encoding cytokines, into tumors and/or surrounding tissue for the treatment and diagnosis of various cancers. As of January 24, 2012, the Company had not generated any revenue from operations.
Advisors' Opinion:- [By James E. Brumley]
How does the old saying go? Beggars can't be choosers? Two weeks ago, yours truly penned some bullish comments regarding OncoSec Medical Inc. (OTCMKTS:ONCS). The long and short of it was, if ONCS could clear a technical ceiling around $0.36, then life would get much easier for the bulls.
- [By James E. Brumley]
If you're looking for the next big biotech breakout stock, then OncoSec Medical Inc. (OTCMKTS:ONCS) deserves a place on your watchlist. This volatile cancer play has been down more than up 2011, but if you look closely at a long-term chart of ONCS, you may find it's already wiggled its way into a new uptrend. And, it may be only a matter of time before the bullish fireworks start to go off.
- [By John Udovich]
Small cap biotech stocks AVEO Pharmaceuticals, Inc (NASDAQ: AVEO), OncoSec Medical Inc (OTCMKTS: ONCS) and MetaStat Inc (OTCBB: MTST) are focused on or are developing treatments or diagnostic technologies for metastatic cancers. In case you aren�� familiar with the term metastasis or metastatic, it�� the�spread of cancer from its primary site to other places in the body as cancer cells break away from a primary tumor, penetrate into lymphatic and blood vessels, circulate through the bloodstream and then grow in a new focus (metastasize) in normal tissues elsewhere in the body. In other words, it�� a dangerous form of cancer, but there are some small cap biotech stocks targeting it for diagnostics or treatment:
Top 10 Low Price Stocks To Invest In Right Now: L-3 Communications Holdings Inc. (LLL)
L-3 Communications Holdings, Inc., through its subsidiary, L-3 Communications Corporation, provides command, control, communications, intelligence, surveillance, and reconnaissance (C3ISR) systems; aircraft modernization and maintenance; and government services in the United States and internationally. Its C3ISR segment offers fleet management sustainment and support, such as procurement, systems integration, sensor development, modifications, and periodic depot maintenance for signals intelligence and communications intelligence systems; strategic and tactical signals intelligence systems; secure data links; secure terminal and communication network equipment and encryption management; and communication systems. The company?s Government Services segment provides communication software support, information technology services, and various engineering development services and integration support; engineering and information systems support services; teaching and training; h uman intelligence support services; command and control systems and software services; and technical and management services. Its Aircraft Modernization and Maintenance segment offers modernization and refurbishments, upgrades and sustainment, maintenance, and logistics support services, as well as turnkey aviation life cycle management services for military and various government and commercial customers. The company?s Electronic Systems segment provides components, products, subsystems, systems, and related services across various business areas, including power and control systems, electro-optic/infrared, microwave, simulation and training, precision engagement, warrior systems, security and detection, propulsion systems, avionics and displays, telemetry and advanced technology, undersea warfare, and marine services. L-3 Communications Holdings, Inc. was founded in 1997 and is based in New York, New York.
Advisors' Opinion:- [By Rich Smith]
The Department of Defense awarded a dozen separate contracts today, worth $949.1 million in aggregate. Nearly half the dollar value was accounted for by a single contract let out for environmental remediation services in New Jersey. But even so, several companies managed to win sizable contracts of their own, including:
- [By Vinay Singh] company provides various security solutions in the United States and internationally.
It has $3.75 per share in cash and enough short-term receivables to take care of its entire long-term debt. Analysts expect $8.34 in EPS for the next fiscal year, and the current stock price is only 9 times that figure, compared to a peer average of 17 times, suggesting L-3 Communications is significantly undervalued.
Impressively, it has similar margins on both EBITDA and operating cash flow in the low double-digits, and its enterprise value implied by the current stock price is only 6.6 times trailing EBITDA. With a free cash flow margin of around 10%, the company should be able to further increase its cash reserve by $14.25 per share next year. **
Also, the company recently raised its quarterly dividend by 10% and authorized the repurchase of as much as $1.5 billion of its stock in a bid to boost shareholder returns. It's no wonder the share count has fallen from 122 million in fiscal 2008 to 94 million at the end of 2012, and considering the management's plans on buybacks, this trend should continue.
Long-term sales growth is where the estimates get tricky. The company faces revenue declines from the winding down of operations in Iraq and Afghanistan, and defense spending cuts due to the rising focus on deficit reduction.
Nevertheless, I expect a steady improvement in free cash flow generation. All told, I think L-3 Communications can grow its free cash flow at a 2-4% rate for the long-term. Discounting that back, it suggests a fair value of about $95.
Raytheon (RTN)
This company also provides various security solutions in the United States and internationally.
It has $12.39 per share in cash and a current ratio of 1.57; the company is liquid. Analysts expect $5.44 in EPS for the next fiscal year, and the current stock price is less than 10 times that figure, compared to a peer average of 17 times, suggesting Raytheon is s
Top 10 Low Price Stocks To Invest In Right Now: Family Dollar Stores Inc.(FDO)
Family Dollar Stores, Inc. operates a chain of self-service retail discount stores primarily for low and middle income consumers in the United States. The company offers consumables, including household chemicals, paper products, candy and snack products, health and beauty aids, hardware and automotive supplies, and pet food products and supplies; and home products, which comprise domestics, housewares, giftware products, and home decor products. It also provides apparel products and accessories consisting of men?s and women?s clothing products, boys? and girls? clothing products, infants? clothing products, shoes, and fashion accessories; and seasonal products and electronics, such as toys, stationery and school supplies, seasonal goods, and personal electronics. As of August 11, 2011, the company operated approximately 7,000 stores in rural and urban settings across 44 states. Family Dollar Stores, Inc. was founded in 1959 and is headquartered in Matthews, North Carolina .
Advisors' Opinion:- [By Rick Aristotle Munarriz]
AFP/Getty Images You can never know in advance all the news that will move the market in a given week, but some things you can see coming. From the year's most important consumer tech exposition to a struggling casual dining chain reporting quarterly results, here are some of the things that will help shape the week ahead on Wall Street. Monday -- Steaks on Skates: When it comes to fast food with throwback charm it's hard to beat the retro ways of Sonic (SONC). There are more than 3,500 "drive-in" locations where guests can pull up to a parking stall and order burgers, shakes, and taters from intercoms. Things haven't been easy for the fast food industry. An improving economy is sending customers to the higher quality fare at fast casual concepts, which combine fresher food with quick service. Sonic has held up better than its more traditional burger-flipping rivals, posting same-restaurant sales growth of nearly 6 percent in its most recent quarter. It will provide financial results for its latest quarter on Monday. Tuesday -- Check In with the Tech Insiders: Consumer tech has never been hotter as consumers snap up smartphones and tablets. CES -- the annual consumer tech powwow -- kicks off on Tuesday for four days of companies showing off their latest gadgets. Wearable computing will naturally be a big part of the event, and we'll see on Tuesday how many companies will be aiming for this market with high-tech bracelets, shoes, glasses, and other accessories. Wednesday -- Ruby Tuesday in the Red: It's not just fast food that's feeling the pain these days. Many of the more ordinary casual dining chains are also struggling to woo the hungry. Ruby Tuesday (RT) is no different. The stock hit new lows three months ago after posting disastrous quarterly results. Comps are plunging, profits have turned to losses, and Ruby Tuesday has missed Wall Street's expectations in back-to-back quarters. Ruby Tuesday's trying. Its latest strategy has been to offer pretzel
- [By Laura Brodbeck]
Next week investors will be waiting for several key earnings reports including Family Dollar Stores�(NYSE: FDO), Micron Technology�(NASDAQ: MU), Constellation Brands�(NYSE: STZ),�IHS (NYSE: IHS), and Sonic (NASDAQ: SONC).
- [By Mike Deane]
Before the opening bell on Thursday, Family Dollar Stores (FDO) announced its Q1 results, posting higher net sales while comparable store sales declined.
FDO Earnings in Brief
-Family Dollar reported Q1 revenues of $2.5 billion, up from last year’s Q1 revenues of $2.42 billion.
-Though revenue rose, the company’s net income for the quarter was down to $78 million from last year’s Q1 net income of $80.28 million.
-FDO reported Q1 EPS of 68 cents, which was down slightly from last year’s Q1 EPS of 69 cents.
-Family Dollar just missed analysts’ expectations of 69 cents EPS on revenues of $2.51 billion.
-Looking ahead to next quarter, FDO reported that it expects EPS in the range of 85 cents to 95 cents, which is well below analysts’ views of $1.21. For FY2014, FDO expects EPS in the range of $3.25 to $3.55, which is also below the analyst view of $3.98.
CEO Commentary
Howard R. Levine, FDO’s chairman and CEO, had the following comments about the company’s lackluster report: “Today, we reported sales and earnings for the first quarter of fiscal 2014 that were in-line with our previously provided guidance. As expected, comparable stores sales were pressured, as we anniversaried strong consumable sales growth last year. In addition, our core customers continued to face economic uncertainties, and the promotional environment intensified. While the top line was pressured, we expanded gross margin and managed inventory levels well. In addition, we continued to make progress in our longer-term initiatives. We opened 126 new stores and renovated, relocated or expanded 179 stores. We also expanded our penetration of private brands, increased our percentage of direct imports, and improved our store manager retention.”
No Change to Dividend
Family Dollar made no mention of change to its dividend payout in its quarterly report. The company last raise
Top 10 Low Price Stocks To Invest In Right Now: Restoration Hardware Holdings Inc (RH)
Restoration Hardware Holdings, Inc. (Restoration Hardware Holdings), incorporated on August 18, 2011, is a holding company. The Company is merchants of home furnishings. Restoration Hardware Holdings offers merchandise assortments across a number of categories, including furniture, lighting, textiles, bath ware, decor, outdoor, garden, and baby and child products. The Company�� business is integrated across its multiple channels of distribution, consists of its stores, catalogs and Websites. As of July 28, 2012, the Company�� operated a total of 73 retail stores, consisted of 71 Galleries and two full line Design Galleries, and 10 outlet stores throughout the United States and Canada. RH is a brand in the home furnishings. During the fiscal year ended January 28, 2012 (fiscal 2011), the Company opened five stores and closed 22 stores. In fiscal 2011, the Company distributed approximately 26.1 million catalogs, and its Websites logged over 14.3 million visits.
Restoration Hardware Holdings operates a Website for its Baby & Child brand at www.rhbabyandchild.com. The Company opened its two full line Design Galleries in Los Angeles in, June 2011 and Houston in November 2011. In May 2011, the Company launched catalog applications for Apple�� iPad and iPhone that enable customers to view and purchase its product assortment. Restoration Hardware Holdings operates three store types: the Company's full line Design Gallery format, approximately between 22,000 and 28,000 gross square feet; its Gallery format of approximately 7,000-15,000 gross square feet, and its Baby & Child Gallery format of approximately 2,000-3,000 gross square feet.
Advisors' Opinion:- [By Brian Nichols]
Restoration Hardware (RH) was Barron's latest weekend victim. To me, Barron's bearish take is reminiscent of its Facebook (FB) call, which was also an article I questioned. The similarities and situations surrounding the two calls include both stocks being post-IPO and both articles implying that stock performance indicates value and future trends. Here is why Barron's is wrong, again!
Top 10 Low Price Stocks To Invest In Right Now: Burlington Stores Inc (BURL)
Burlington Stores, Inc., incorporated on February 13, 2013, is a national off-price retailer of branded apparel, operating 503 stores, inclusive of an Internet store, in 44 states and Puerto Rico. The Company offers its merchandise using an Every Day Low Price (EDLP) model with savings up to 60-70% off department and specialty store regular prices. It provides its customers with a selection of fashionable branded product in women�� ready-to-wear apparel, menswear, youth apparel, baby products, footwear, accessories, home goods and coats. The Company merchandise from over 3,500 vendors, with a focus on nationally-recognized brands. This vendor breadth provides its customers with a treasure hunt experience of searching for great brands at great value.
The Company�� average store size is approximately 80,000 square feet, which is two to three times the size of its off-price competitors��stores. Its larger store size has allowed the Company to offer more categories and substantially more breadth in each product category than its off-price competitors and to establish ourselves as a destination for select categories, including coats, youth and baby, special-occasion dresses and men�� tailored apparel.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
Burlington Stores (NYSE: BURL) shares shot up 15.02 percent to $29.79 on Q4 results. Burlington Stores reported its Q4 earnings of $1.07 per share, versus analysts' estimates of $1.03 per share.
No comments:
Post a Comment